Can Trazodone Increase Heart Rate?
Yes, trazodone can cause tachycardia and increase heart rate through multiple mechanisms, including as a manifestation of serotonin syndrome and through direct cardiac effects.
Direct Cardiac Effects and Arrhythmias
The FDA label explicitly warns that trazodone may be arrhythmogenic, with identified arrhythmias including tachycardia with syncope, ventricular tachycardia, and torsade de pointes 1. These cardiac effects can occur even at doses of 100 mg or less 1.
Trazodone should be avoided in patients with:
- Pre-existing cardiac arrhythmias 1
- Known QT prolongation 1
- History of cardiac disease (requires close monitoring if used) 1
- Symptomatic bradycardia, hypokalemia, or hypomagnesemia 1
Serotonin Syndrome as a Mechanism
Tachycardia is a cardinal feature of serotonin syndrome, which trazodone can precipitate 1. The FDA label specifically lists tachycardia as a sign of autonomic instability in serotonin syndrome, along with labile blood pressure, diaphoresis, flushing, and hyperthermia 1.
Risk is increased with:
- Concomitant serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, fentanyl, lithium) 1
- MAOIs (contraindicated combination) 1
Clinical Evidence of Tachycardia
Research demonstrates tachycardia as a significant adverse effect:
- In a fibromyalgia study, tachycardia was the most frequent and severe side effect, reported by 21.2% of patients receiving trazodone at doses of 50-300 mg/day 2
- Veterinary studies showed immediate transient tachycardia (184 beats/min) after IV administration, with heart rate increases significantly associated with plasma drug concentrations 3
- A 2025 study confirmed trazodone increased average heart rates, minimum heart rates, and reduced heart rate variability in dogs 4
Mechanisms Beyond Serotonin Syndrome
Trazodone can increase heart rate through:
- Anticholinergic effects that reduce parasympathetic tone 4
- Reflex tachycardia secondary to orthostatic hypotension and vasodilation 1
- Direct ion channel effects on cardiac action potentials, inhibiting hERG, sodium, and calcium channels 5
Post-Marketing Surveillance
The FDA reports multiple cardiac adverse events including palpitations, tachycardia, atrial fibrillation, and ventricular tachycardia in post-marketing surveillance 1. Prolonged QT interval and torsade de pointes have been documented at doses of 100 mg per day or less 1.
Clinical Monitoring Recommendations
Patients on trazodone require monitoring for:
- Emergence of tachycardia or palpitations 1
- Signs of serotonin syndrome (especially with concomitant serotonergic drugs) 1
- Orthostatic vital signs, as hypotension can trigger reflex tachycardia 1
- ECG monitoring in patients with cardiac disease or risk factors 1
Common Pitfall
The most important pitfall is assuming trazodone is cardiac-safe because it lacks the anticholinergic effects of older tricyclic antidepressants 6. However, trazodone carries significant arrhythmogenic potential through multiple mechanisms, and tachycardia can be an early warning sign of serious cardiac toxicity 2, 6.